Inside IPEC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside IPEC

Inside IPEC: IPEC Tackles Monographs, Impurities, Particles, and More

December 2, 2011

Pharmaceutical Technology

As the excipient supply chain becomes more complex, industry must up the ante to comply with new standards and regulations.

Inside IPEC: IPEC–Americas Releases Good Distribution Practices Audit Guide

March 2, 2011

Pharmaceutical Technology

A new audit guide aims to improve supply-chain security and supplier qualification practice.

Inside IPEC: Global Initiatives to Expand to Latin America

December 2, 2010

Pharmaceutical Technology

IPEC extends its reach to Brazil and Argentina in an effort to harmonize excipient best practices.

Inside IPEC–Americas: Evaluating Excipient Stability

September 2, 2009

Pharmaceutical Technology

IPEC's new stability testing guide takes into account the full supply chain's storage conditions.

Inside IPEC: Good Distribution Practices for Pharmaceutical Excipients

May 2, 2009

Pharmaceutical Technology

The GDP committee of IPEC–Europe is trying to seal one more broken link in the supply chain. This article contains bonus online-exclusive material.

Inside IPEC: Regulation for Excipients is Brewing Across the Atlantic

February 2, 2009

Pharmaceutical Technology

Without any GMP guidelines for excipients in Europe, change can't come soon enough for some industry groups.

IPEC's New Safety Evaluation Procedure: A Q&A with IPEC Chairman Dave Schoneker

November 2, 2008

Pharmaceutical Technology

IPEC Chairman Dave Schoneker discusses current efforts toward facilitating regulatory reviews of new excipients.

Inside IPEC: Dual-Use Labeling

July 2, 2008

Pharmaceutical Technology

Clear labels for substances that can be used as excipients, APIs, or both are critical to end-product use.

Inside IPEC–Americas: Excipient Audits and API Audits are Worlds Apart

May 2, 2008

Pharmaceutical Technology

The less complex nature of excipient manufacturers, as compared with API manufactures, carries many benefits.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here